



President's Office / Bureau du Président

March 16, 2015

Minister Teresa Wat
Minister of International Trade
Parliament Buildings
Victoria BC V8V 1X4

Dear Minister Wat,

14855

Ministry of International Trade	
Minister's Office	
RECEIVED	
APR 10 2015	
<input type="checkbox"/> MO Response	<input type="checkbox"/> INFO File
<input type="checkbox"/> DMO Response _____	
CC: _____	
OTHER: _____	

On behalf of Canada's Research-Based Pharmaceutical Companies (Rx&D), I am writing to provide you an update on Rx&D's involvement and commitment to the Asia-Pacific Economic Cooperation (APEC) forum and to highlight the leadership Canada has shown to help strengthen ethical standards in APEC-member economies, while also enhancing our country's competitiveness.

Rx&D serves as the leading association of research-based pharmaceutical companies operating in Canada with more than 50 member companies. Our members are committed to ethical interactions, recognizing that they are at the heart of patient-centered healthcare by improving access to the safe and effective use of medicines as well as ensuring decisions are made in patients' best interest. High ethical standards also facilitate innovation and cross-border trade by creating fair and predictable business conditions, harmonizing best practices across markets, and reducing compliance risk and legal costs. These benefits are particularly crucial for the small and medium enterprises that comprise a significant majority of biopharmaceutical firms conducting trade in the APEC region.

In 2010, the "Business Ethics for APEC Small and Medium Enterprises" initiative championed the creation of APEC principles for voluntary codes of business ethics in several sectors of importance to small and medium enterprises (SMEs) in the region, including the medical device and biopharmaceutical sectors. Rx&D was invited by the U.S. Department of Commerce in 2011 to serve as Industry Co-Chair of the Expert Working Group that developed the APEC Mexico City Principles. Heightened ethical interaction in these healthcare sectors are crucial to enhancing patient access to safe and effective medical products, promoting SME innovation, building SME export confidence and ultimately ensuring decisions are made in the best interests of patients.

Industry leaders in the biopharmaceutical sector have strongly supported the APEC Business Ethics Initiative over the past five years since it was launched. Most recently, notable progress was made in 2014 through our industry's public-private partnership with 21 governments through APEC. Together, we have facilitated the development of 18 biopharmaceutical and medical device industry association codes across nine APEC economies where they previously did not exist, expanding high standard practices to nearly 14,000 companies across the Asia Pacific region. Please see the attached backgrounder for more detail on work that has been accomplished by the biopharmaceutical sector since 2010.

The 2014 APEC Business Ethics for SMEs Forum in Nanjing, China was an important milestone for this initiative. The event convened over 200 participants from more than 80 organizations across 20 APEC economies, including dozens of SMEs and their industry associations, to strengthen regional capacity through ethics training as well as to provide strategic vision and recommendations for the initiative. The



Forum's plenary session achieved unanimous support for the "Nanjing Declaration" containing strategic goals and numerous actions for key stakeholders in the biopharmaceutical and medical device sector. Subsequently endorsed by APEC SME Ministers and APEC Ministers, the Declaration provides significant, multi-stakeholder buy-in to advance this initiative through 2020. We understand preparations are advancing very well for the next APEC Business Ethics for SMEs Forum to take place in Manila, Philippines on 19-20 August 2015.

Members of our industry are united in their belief that high ethical standards promote a level playing field for all enterprises across the Asia Pacific region. Harmonizing best practices in the biopharmaceutical sector also makes it easier for small and large companies alike to conduct business across borders. We are committed to taking a leading role and to driving results year after year.

At Rx&D we support this work because we know well that behaving ethically is both good for patients and good for business. We're convinced that levelling the playing field by establishing high ethical standards will enable our members to increase exports to fast-growing markets throughout Asia, preserving and strengthening the financial security of hard-working Canadians and generating jobs, growth and long-term prosperity across the country.

Opportunities in the fast-growing Asia-Pacific region are significant for Canadian exporters from many of Canada's key economic sectors. Asia-Pacific countries represent huge markets and great economic opportunities. Between 2010 and 2014, Canada's imports from China alone grew by almost 32 per cent, while Canadian exports to China grew by over 45 per cent. In fact, China has now surpassed the United Kingdom to become Canada's second-largest export destination, after the United States.

The Government of Canada's continued commitment to supporting this initiative is yet another example of our country's leadership on the world stage. Indeed, the global community is paying attention. These positive developments and Canada's leadership on the APEC Business Ethics initiative can enhance our public image on the global stage and strengthen Canada's global economic competitiveness.

We are immensely proud of the measurable outcomes we have achieved so far and we look forward to working with you to build on our successes to date.

In addition to this letter, I have included some further information about the initiative, as well as information about the valuable contribution Rx&D member companies make in communities across Canada.

As this initiative continues to advance, I will keep you updated, especially on activities and initiatives that will create win-win opportunities for both sides.

In the meantime, should you require any more information, please do not hesitate to get in touch with me.

Sincerely,

A handwritten signature in cursive script that reads "Russell Williams".

Russell Williams,
President

Business Ethics for APEC SMEs Initiative

Biopharmaceutical Sector

The Business Ethics for APEC SMEs Initiative was launched in 2010 to strengthen ethical standards across APEC member economies, helping IFPMA member associations and companies in the Asia-Pacific region reduce competitive disadvantage and compliance risk. The initiative's biopharmaceutical sector program has demonstrated notable success in the development and implementation of codes of ethics by local industry associations in alignment with APEC's Mexico City Principles (modeled on the IFPMA Code).

APEC Member Economies (21)

Australia, Brunei, Canada, Chile, China, Hong Kong, Indonesia, Japan, Korea, Malaysia, Mexico, New Zealand, Papua New Guinea, Peru, Philippines, Russia, Chinese Taipei, Thailand, Singapore, United States, Viet Nam

2014 Activities Update

Business Ethics Forum: Scheduled for 1-3 Sept 2014 in Nanjing, China, this event has two key objectives: (A) strengthen the capacity of non-IFPMA biopharmaceutical industry associations to draft and implement high standard codes of ethics through intensive training sessions (working toward a target of doubling the number of associations in the region with a code of ethics by 2015); and (B) convene stakeholders during a high-level plenary session to discuss the respective role of governments, industry and healthcare professionals. The plenary session is expected to produce a "Nanjing Declaration" that outlines strategic next steps for each stakeholder and the initiative through 2020.

Quarterly Survey: The initiative's Secretariat is undertaking quarterly online and phone surveys of biopharmaceutical industry associations to understand their progress in the development, adoption and implementation of their code of ethics as well as to inform the work of mentor teams assigned to support these associations. The Q1 2014 survey examined 54 associations and found that 21 non-IFPMA member associations from 12 APEC economies (Canada, China, Indonesia, Japan, Malaysia, Mexico, New Zealand, Peru, Philippines, Chinese Taipei, Thailand and Viet Nam) self-report as having adopted -- or are in the process of adopting -- a code aligned with The Mexico City Principles. The next survey is currently underway.

Website: Websites for both the overall Business Ethics for APEC SMEs Initiative and its biopharmaceutical sector program will launch in June 2014 (see links above). Developed under the leadership of Rx&D, the biopharmaceutical website will serve as a leading source of code alignment information and training resources for local industry associations and companies.

Note: Please see the attached overview for a brief history of the initiative's activities from 2010-2013.

Biopharmaceutical Sector

2012 APEC assns w/ codes: 25

Current APEC assns w/ codes: 35

IFPMA assns in APEC: 18

Satellite Websites:

<http://businessethics.apec.org> &
<http://mcprinciples.apec.org> or
www.mcprinciples.org

Financial & In-Kind Support

The biopharmaceutical program of this initiative would not be possible without the financial and in-kind contributions of several IFPMA member associations and companies. This year we recognize IFPMA, Rx&D (Canada), PhRMA (US), RDPAC (China), JPMA (Japan), HKAPI (Hong Kong), Johnson & Johnson, Eli Lilly, AbbVie, Merck Serono, AstraZeneca, Astellas, and Bayer for contributing a total of US\$200,000. IFPMA member associations and companies who wish to support this initiative may contact Mr. Russell Williams, President of Rx&D & Chair of the IFPMA Code Compliance Network (rwilliams@canadapharma.org).

Business Ethics for APEC SMEs Initiative

OVERVIEW

Small and Medium Enterprises (SMEs) can serve as an engine of economic growth as long as they operate and innovate in ethical business environments. Unethical business practices disproportionately impact SMEs. More than 70% of SMEs in transition economies perceive corruption as an impediment to their business and one-third see corruption as a major business obstacle.¹

To address this issue, in 2010 APEC SME Ministers called for APEC codes of ethics in key sectors. This call launched the *Business Ethics for APEC SMEs Initiative*, which has focused on: developing high standard APEC principles for codes of ethics in key sectors; capacity building to assist interested organizations to draft and implement codes consistent with high standard APEC principles; and generating awareness among key stakeholders. The initiative has thus far focused on the medical device, biopharmaceutical, and construction/engineering sectors.

The initiative benefits resource-constrained SMEs by providing clarity and harmonization in industry ethics practices, addressing the supply side of corruption through collective action, and promoting the long-term sustainability of SMEs. Collectively, this effort is improving business practices for thousands of small, medium and large manufacturers, importers and distributors in all three sectors.

With the support and participation of all 21 APEC member economies, as well as \$2.2 million (USD) in APEC funding and in-kind support from governments and other stakeholders, the initiative has achieved significant results since 2010, notably:

- Medical device sector codes of ethics where ones previously did not exist in at least 4 APEC economies (Chile, Malaysia, Peru, Singapore), as well as higher standard codes in 3 APEC economies (Russia, Mexico and Indonesia). Additional medical device codes of ethics are under development in at least 3 APEC economies (China, the Philippines and Chinese Taipei).
- Biopharmaceutical codes of ethics where ones previously did not exist in at least 4 APEC economies (China, Malaysia, Chinese Taipei, and Vietnam). Additional biopharmaceutical codes of ethics are under development in at least 2 APEC economies (Peru and the Philippines). In October 2013, China's nine largest biopharmaceutical industry associations convened in Beijing to sign a "Declaration of the Implementation of Pharmaceutical Enterprise Ethical Business Practices" that commits the associations' thousands of member companies to align with the Mexico City Principles.
- Establishment of a network of over 100 ethics trainers spanning all three sectors to advance implementation of codes aligned with the APEC principles.

These achievements were due to APEC capacity building efforts that have included:

- Development of APEC Principles for Voluntary Codes of Ethics in all three sectors (endorsed by APEC Ministers in 2011², APEC Ministers Responsible for Trade in 2012³ and APEC Leaders in 2012⁴):

¹ The Business Environment and Enterprise Performance Survey (BEEPS) – a joint initiative of the European Bank for Reconstruction and Development (EBRD) and the World Bank.

² 2011 APEC High Level Policy Dialogue on Open Governance and Economic Growth: http://www.apec.org/Meeting-Papers/Ministerial-Statements/Annual/2011/2011_amm/2011_governance.aspx

- Medical Device sector (Kuala Lumpur Principles):
http://aimp.apec.org/Documents/2011/MM/SMEMM/11_smemm_009.pdf
- Biopharmaceutical sector (Mexico City Principles):
http://aimp.apec.org/Documents/2011/SOM/CSOM/11_csom_021.pdf
- Construction and Engineering sector (Hanoi Principles):
http://aimp.apec.org/Documents/2011/SOM/CSOM/11_csom_022.pdf
- Workshops to draft working codes consistent with the APEC principles for the medical device sector (Brunei Darussalam, 2012) and the biopharmaceutical sector (Taipei, 2012).
- The APEC Train-the-Trainer Workshop to implement codes consistent with the APEC principles and assemble a network of ethics trainers throughout the region (Kuala Lumpur, 2013).
- Outreach to key stakeholders through a high-level stakeholder awareness meeting in Nusa Dua, Indonesia (2013) that convened leaders of physician and hospital associations, senior health regulators and anti-corruption officials from 17 APEC economies. The meeting resulted in the Nusa Dua Statement on strengthening ethical interactions among the region's key healthcare stakeholders.⁵

To further advance this initiative the first APEC Business Ethics Forum will be held in Nanjing, China on 1-3 September 2014. China is one of 14 APEC economies to co-sponsor the Forum. The Forum will progress code of ethics implementation towards a target of doubling the number of industry associations with codes of ethics by 2015. The Forum will also convene key stakeholders to address ethical issues confronting the medical device and biopharmaceutical sectors.

For more information on this initiative, please contact Lynn Costa (Lynn.Costa@trade.gov), Project Overseer & Senior Trade Development Advisor, U.S. Department of Commerce.

³ 2012 APEC Ministers Responsible for Trade Meeting Joint Statement: http://www.apec.org/Meeting-Papers/Ministerial-Statements/Trade/2012_trade.aspx

⁴ 2012 APEC Leaders' Declaration: http://www.apec.org/Meeting-Papers/Leaders-Declarations/2012/2012_aelm/2012_aelm_annexE.aspx

⁵ Nusa Dua (Bali) Statement: http://mddb.apec.org/Documents/2013/SMEWG/HLM/13_smewg37_hlm_statement.doc



**Asia-Pacific
Economic Cooperation**

2014/SMEMM/020a

Agenda item: 6.2.8

**2014 APEC Business Ethics for SMEs Forum:
Nanjing Declaration on Promoting Ethical
Environments in the Medical Device and
Biopharmaceutical Sectors Through 2020**

Purpose: Consideration
Submitted by: United States



**21st Small and Medium Enterprises Ministerial
Meeting
Nanjing, China
5 September 2014**

Nanjing, China, 2 September 2014

2014 APEC Business Ethics for SMEs Forum:

Nanjing Declaration – Promoting Ethical Environments in the Medical Device and Biopharmaceutical Sectors through 2020

1. We, representatives from healthcare providers and professional organizations, anti-corruption agencies, health ministries, health regulatory agencies, economic ministries, medical device and biopharmaceutical associations, industry and patient organizations from across the APEC region, convened in Nanjing, China today to chart the future course of our joint efforts to advance the “Business Ethics for APEC SMEs Initiative” in the medical device and biopharmaceutical sectors. We do so with knowledge that nearly 1,000 stakeholder representatives have engaged in this initiative from all 21 APEC member economies to strengthen ethical business practices for the medical device and biopharmaceutical sectors, including more than 10,000 SMEs, and that this initiative has proven to be an effective model.

2. We reaffirm our support for The Kuala Lumpur Principles for Voluntary Codes of Ethics in the Medical Device Sector and The Mexico City Principles for Voluntary Codes of Ethics in the Biopharmaceutical Sector. These principles represent the highest global standards in ethical practices for each sector and strengthen the ability of SMEs to sustainably operate and engage in cross-border trade.

3. We extend our appreciation to APEC Economic Leaders, APEC Ministers, APEC Ministers Responsible for Trade (MRT), APEC SME Ministers and the APEC Business Advisory Council (ABAC) for their endorsement of this initiative. We recall their statements guiding APEC economies to support the local elaboration and implementation of codes of ethics aligned with APEC principles for industry, healthcare professional organizations, and other stakeholders.

4. We extend our appreciation to the APEC SME Working Group for its leadership in convening industry, government and non-governmental organizations to develop the APEC principles, providing capacity building assistance to facilitate their implementation, and supporting the first APEC Business Ethics for SMEs Forum.

5. One year ago in Nusa Dua, Indonesia, we recognized that ethical collaboration among industry, healthcare providers and governments promotes broad patient access to life-saving and health-enhancing medical technologies and therapies and is essential to the development of new innovations that meet patient needs. We also agreed that each stakeholder has a responsibility to take further steps to promote an ethical environment. The Nusa Dua Statement¹ issued on 3 September 2013 established that each stakeholder has a unique and important role to promote ethical healthcare environments, including:

- **The Medical Device and Biopharmaceutical Industry** should adhere to high ethical standards, such as the APEC principles, as well as all applicable laws and regulations, as part of their mission to help patients by developing and making life-saving and health-enhancing medical technologies and therapies available.
- **Healthcare Professionals** have a duty to act in the best interests of patients and recognize the importance of their role in communicating the importance of interactions based on ethical principles, such as the APEC principles, including through complementary activities and ongoing dialogue with all stakeholders.
- **Health Ministries and Health Regulatory Agencies** should recognize the value of industry codes of ethics and encourage all stakeholders to support ethical principles, such as the APEC principles, and national and local industry codes of ethics.

¹ Nusa Dua (Bali) Statement: http://mddb.apec.org/Documents/2013/SMEWG/HLM/13_smewg37_hlm_statement.doc

- **Government and Private Procurement Entities** should procure health products and services based on transparent, ethical, clear, and accountable policies, processes and procedures.
- **Anti-corruption Authorities** should objectively apply clear laws, welcome industry self-regulation as complementary to law enforcement, and encourage all companies to adopt and adhere to uniform ethical principles, such as the APEC principles, and national and local industry codes of ethics.

6. Ethical interactions between industry and healthcare professionals are essential to provide healthcare providers and their patients with the information they need to make informed healthcare decisions. Recognizing our shared commitment to acting in the best interest of patients, we agree on a collective vision for the future of this initiative with recognition that there is more to be done to achieve regional alignment in ethical business practices for both sectors. We declare our intention to APEC SME Ministers, APEC Ministers and APEC Leaders to achieve the following goals and call upon APEC economies and stakeholders to undertake the following actions to achieve them, respecting the diversity of healthcare systems:

Goals	Actions
<p><i>For the Medical Device and Biopharmaceutical Industry:</i> <u>Double the number of medical device and biopharmaceutical industry associations that have adopted codes of ethics from 33 in 2012 to 66 or more by 2015 and work toward universal adoption and implementation of the APEC Principles by 2020.</u></p>	<ul style="list-style-type: none"> • Convene the APEC Business Ethics for SMEs Forum on an annual basis (2015-2020) prior to the APEC SME Ministerial Meeting and hosted by the APEC chair economy. • Establish a task force with other stakeholders to secure funding for an "APEC Business Ethics Capacity Building Fund" by 2015 to support the Forum and associated capacity building for industry -- as well as governments, healthcare professionals and other stakeholders -- through 2020. • Formalize the "APEC Medical Device Working Group on Ethics" and "APEC Biopharmaceutical Working Group on Ethics" in 2014 with a mandate to: identify priority training areas for industry, governments, healthcare professionals and other stakeholders; implement training, including capacity building for industry associations with and without codes; formalize/manage each sector's trainer network and online resources; and monitor progress, submitting an annual report to the "Business Ethics for APEC SMEs Initiative" for transmission to the APEC SME Working Group and other relevant APEC fora. • By 2015, the "APEC Medical Device Working Group on Ethics" and "APEC Biopharmaceutical Working Group on Ethics" will review the APEC principles to ensure that they continue to reflect the highest standards in business practices. • Establish an "APEC Code of Ethics Compendium for the Medical Device and Biopharmaceutical Sectors" by 2015 and updated annually thereafter to assist SMEs seeking to conduct business throughout the region. The compendium will contain a copy of each industry association's most recent code of ethics and analysis undertaken by each sector's working group indicating where there is alignment with the APEC principles. The compendium will be presented each year to the APEC SME Working Group, transmitted directly to governments, and made







	public for SMEs to access via the Business Ethics for APEC SMEs website (http://businessethics.apec.org).
<u>For the Medical Device and Biopharmaceutical Industry: Implementation of association codes by a majority of member companies by 2017.</u>	<ul style="list-style-type: none"> By 2015, the "APEC Medical Device Working Group on Ethics" and "APEC Biopharmaceutical Working Group on Ethics" will: (a) convene a best practices exchange with APEC economies and industry associations to support member company code implementation; (b) develop training materials to facilitate code implementation by member companies; (c) monitor progress; and (d) report on the status of member company implementation in 2016 and 2017.
<u>For Governments: Support and endorse local partnerships in APEC economies between relevant government ministries/agencies and the medical device and biopharmaceutical industries to advance industry's voluntary efforts to strengthen ethical business practices.</u>	<ul style="list-style-type: none"> Support local partnerships in APEC economies between relevant ministries/agencies (e.g., health ministries and health regulatory authorities, government procurement entities, economic ministers and anti-corruption authorities) and the medical device and biopharmaceutical industries to advance industry's voluntary efforts to strengthen ethical business practices (examples of partnership between government and industry include associations forming integrity pacts with relevant government ministries/agencies, the formation of a local business ethics centre, or governments actively supporting companies to develop and implement high-standard codes of ethics). Leverage the "APEC Medical Device Working Group on Ethics" and "APEC Biopharmaceutical Working Group on Ethics" to recommend and implement the capacity building required to support local partnerships. Use the "APEC Business Ethics Capacity Building Fund" to help fund capacity building activities.
<u>For Governments: Support and endorse local partnerships in APEC economies between relevant government ministries/agencies and healthcare professional organizations.</u>	<ul style="list-style-type: none"> Support local partnerships in APEC economies between relevant ministries/agencies (e.g., health ministries and health regulatory authorities, government procurement entities, economic ministers and anti-corruption authorities) and healthcare professional organizations. Leverage the "APEC Medical Device Working Group on Ethics" and "APEC Biopharmaceutical Working Group on Ethics" to recommend and implement the capacity building required to support local partnerships. Use the "APEC Business Ethics Capacity Building Fund" to help fund capacity building activities.
<u>For Healthcare Professionals (HCPs)²: Support development and implementation of HCP</u>	<ul style="list-style-type: none"> Develop an "APEC Consensus Framework for Ethical Collaboration" between the region's medical device and biopharmaceutical industries and healthcare professional

² The term "Healthcare Professionals" includes those individuals and entities that purchase, lease, recommend, use or arrange for the purchase or lease of, or prescribe medical products. This includes both clinical and non-clinical individuals who make product-related decisions of the type described above. This is a broad definition, intended to encompass anyone with material influence over purchasing decisions. Note that there may be laws and other codes applicable to relationships with Healthcare Professionals, including relationships with government employees.











<p><u>codes of conduct consistent with the APEC Principles, working towards regional alignment by 2020.</u></p>	<p>organizations. Establish a work plan for joint collaboration to implement the Consensus Framework, including the development and implementation of HCP codes of conduct consistent with the APEC principles.</p> <ul style="list-style-type: none"> • Leverage the "APEC Medical Device Working Group on Ethics" and "APEC Biopharmaceutical Working Group on Ethics" to recommend and implement capacity building required to support implementation of the "APEC Consensus Framework for Ethical Collaboration", including the development and implementation of HCP codes of conduct consistent with the APEC principles.
<p><i>For non-government organizations, in particular patient organizations:</i> <u>Promote ethical environments in the medical device and biopharmaceutical sectors.</u></p>	<ul style="list-style-type: none"> • Support partnerships with government agencies, HCPs and industry associations.

Over 1.7 billion in NEW investments announced since January 2011









Rx&D member companies continue to demonstrate their commitment to Canada with investments in research, capacity building, community development and life-sciences education. A total of \$1,753,460,000.00 worth of new investments have been announced since January 2011.

Date	Company	Announcement	Investment	Province
2010 - 2011	 Janssen	Western Canada Innovation Agreement: This agreement between COSAT (Corporate Office of Science and Technology) of Johnson & Johnson establishes a business partnership with the provinces of Alberta, British Columbia on early stage compounds in research and development.	\$1,300,000.00	AB, BC
2011	 Janssen	Investment in Health Partners International Canada (HPIC) which provides medical aid through Canadian doctors, aid organizations and government agencies to impoverished communities and countries.	\$325,000.00	National
2011	 Janssen	Donation to Safe Kids Canada, which uses a collaborative and innovative approach to develop partnerships, conduct research, educate and advocate to prevent serious injuries among children, youth and their families.	\$210,000.00	National
2010 - 2011	 Janssen	COSAT – MaRS Co-Managed Fund. This partnership between the Corporate Office of Science and Technology of Johnson & Johnson and the MaRS Discovery District in Toronto establishes a working agreement to support the development of early stage medical innovations.	\$200,000.00	ON
1-Jan-2011	 Bayer	Bayer HealthCare Pharmaceuticals (Bayer) and EndoCeutics Inc., Québec, are proud to announce the signing of an exclusive international collaborative agreement for Phase III development and marketing of a new treatment for women.	\$330,000,000.00	QC
1-Jan-2011	 Bristol-Myers Squibb Canada	Bristol-Myers Squibb announced the renewal of an existing \$1 million research grant to the Institut de recherche en immunologie et cancer (IRIC), at the Université de Montréal.	\$1,000,000.00	QC









24-Jan-2011		The Pfizer-FRSQ-MSSS Chronic Disease Fund: this FRSQ-coordinated research grant program is aimed at evaluating chronic disease prevention and management initiatives.	\$5,000,000.00	QC
26-Jan-2011		Investment in the Quebec Consortium for Drug Discovery (CQDM) supporting early-stage biopharmaceutical research in Quebec.	\$5,000,000.00	QC
16-Feb-2011		Investment in the Quebec Consortium for Drug Discovery (CQDM) to strengthen innovative research in Quebec	\$300,000.00	QC
18-Feb-2011		AmorChem, a Quebec-based life science venture capital fund that will provide the necessary resources to advance research projects through the registration and marketing stages.	\$6,800,000.00	QC
5-Apr-2011	 	Purdue Pharma Canada and Pfizer Canada Inc. each contributed \$130,000 the Nova Scotia Chronic Pain Collaborative Care Network (NSCPCCN).	\$260,000.00	NS
17-May-2011		New 15,000-square-foot dedicated manufacturing suite. The new facility provides uni-dose packaging of solid oral dosage in four Class 100000 clean rooms, each ensuring low relative humidity (20%), controlled temperature and controlled residual oxygen to 4%.	\$9,000,000.00	QC
31-May-2011		Creation of the GSK-MaRS Innovation Fund that will support and fast-track the commercialization of some of the country's most promising translational research coming from 16 leading academic health sciences centres, hospitals and universities derived from the MI membership.	\$750,000.00	National
01-Jun-2011		Abbott has given funds to McMaster University to create an education chair of rheumatology, which will be matched by the Department of Medicine of the Michael G. DeGroote School of Medicine.	\$1,000,000.00	ON
01-Jun-2011		Eli Lilly Canada joined the Quebec Consortium for Drug Discovery (CQDM) as a member supporting the Explore Program. The Explore Program is aimed at testing new unconventional and highly innovative research projects that may strongly impact the drug discovery process. Eli Lilly Canada joined with a three year commitment.	Amount Undisclosed	QC



01-Jun-2011	 	Office expansion of \$1.3 million dollars; mainly for the new Oncology Business Unit.	\$1,300,000.00	QC
09-Jun-2011		Ontario is helping GlaxoSmithKline Inc. – a world-leading research-based pharmaceutical company – attract new investment, create 70 new jobs and protect 300 existing jobs in Mississauga. With the province's support GlaxoSmithKline Inc. will expand their state-of-the-art advanced manufacturing facility in Mississauga. This expansion will help bring new products to market and enable the global supply of the company's dermatological products such as creams, ointments, lotions, and foams – the first capability of its kind in Ontario. Ontario is supporting the expansion of the state-of-the-art manufacturing facility with \$3.6 million – GlaxoSmithKline Inc. is providing more than \$30 million towards the project.	\$30,000,000.00	ON
15-Jun-2011		Manitoba's first-ever research chair in the immunobiology of infectious disease at the University of Manitoba. The \$3 million investment for the Chair in the Immunobiology of Infectious Diseases will help focus existing research at the U of M in the areas of immunology, infectious diseases, systems biology and public health while continuing to build Manitoba's reputation as a global leader. The Province of Manitoba is investing \$500,000, the University of Manitoba is investing \$1 million and GSK's Pathfinders Fund is providing \$1.5 million.	\$1,500,000.00	MB
15-Jun-2011		A major international study of 11,000 elderly persons with high blood pressure (hypertension) will be led and managed by the Population Health Research Institute (PHRI) of Hamilton Health Sciences and McMaster University, thanks to a \$40-million investment in Ontario by Novartis.	\$40,000,000.00	ON
21-Jun-2011		Modernized of Pfizer's head office, aimed at bringing together under one roof all the Canadian head office employees in the Biopharmaceutical and Animal Health Divisions.	\$22,000,000.00	QC
22-June-2011		Opening of a new \$101 million vaccine research and development facility at Sanofi Pasteur's Connaught Campus in North Toronto. The province of Ontario contributed \$13.9 million to the project through the Biopharmaceutical Investment Program.	\$101,000,000.00	ON
16-Aug-2011		Ontario is helping Roche Canada expand its Mississauga facility by making it the home of a new Global Pharmaceutical Development site. This will create 200 new specialized research jobs in the region.	\$190,000,000.00	ON



Aug-2011	GlaxoSmithKline Inc., Merck Canada Inc., Astra Zeneca Canada Inc., Amgen Canada Inc., Eli Lilly Canada Inc., Pfizer Canada Inc., and Novartis Pharmaceuticals Canada Inc.	The Initiative for Sustainable Health Care within the Faculty of Pharmaceutical Sciences at the University of British Columbia will provide a neutral, balancing voice and an opportunity for ongoing dialogue and research on economic principles of healthcare sustainability, with a focus on the role of pharmacy and pharmaceuticals in effecting change. Seven Rx&D member companies are founding members, each having committed \$300,000 over five years.	\$2,100,000.00	BC
22-Aug-2011		Roche Canada's support of a Vasculitis and Scleroderma Fellowship through the Division of Rheumatology at the University of British Columbia (UBC)	\$70,000.00	BC
25-Aug-2011		The Ontario government is partnering with Eisai to establish its Canadian headquarters in Mississauga, creating 11 new jobs and protecting one other position. Eisai's expansion will increase access to a variety of therapies and medications for advanced breast cancer, Alzheimer's disease, epilepsy and other conditions. The Rx&D member company will also continue to invest in clinical trials in Canada supporting public and private research institutions and organizations.	Amount Undisclosed	ON
29-Aug-2011		Donation of \$2.7 million to fund the establishment of the Canadian Depression Biomarker Network, a Canada-wide research study into the biomarkers of depression that will involve six academic centres across Canada, including the Ontario Cancer Biomarker Network, the University Health Network, McMaster University, Queen's University, the University of British Columbia and the University of Calgary.	\$2,700,000.00	ON, BC, AB
1-Sep-2011		Administrative building in Quebec City.	\$18,000,000.00	QC
2-Sep-2011		Merck's collaboration with Zymeworks, a privately held Vancouver biotechnology company for the development of potentially novel antibodies.	Amount Undisclosed	BC
26-Sep-2011		Hoffmann-La Roche Ltd. (Roche) and CDRD's commercial arm, CDRD Ventures Inc. (CVI), have entered into a Strategic Collaboration Agreement whereby Roche has committed several million dollars to support and jointly develop innovative health research technologies under the management of CVI.	Amount Undisclosed	National



29-Sep-2011		Announcement by GlaxoSmithKline (GSK) Inc. of a joint investment with the Canadian Institutes of Health Research (CIHR) and the Université de Sherbrooke for the creation of a new Research Chair in Quebec on the causes of Type 2 Diabetes. The newly created Chair's activities will be supported by a \$1 million endowment and a matching grant of \$375,000 over a five-year period.	\$1,000,000.00	QC
21-Oct-2011		Lundbeck Canada is contributing \$250,000 over five years to The Best Care for Life Campaign, in support of the Mental Health Mission of the McGill University Health Centre Foundation MUHC.	\$250,000.00	QC
28-Oct-2011		Shire Canada Inc. made a \$200,000 gift to The Hospital for Sick Children Foundation. A joint contribution of Shire Canada's ADHD Business Unit and Shire Human Genetic Therapies (Canada) teams, the funds will go towards the Hospital's new Research & Learning Tower as well as the ADHD section of its About Kids Health program.	\$200,000.00	ON
1-Nov-2011		Merck Canada's announcement of the investment of \$33.2 million to modernize its Pointe Claire Manufacturing facility.	\$33,200,000.00	QC
10-Nov-2011		GlaxoSmithKline Inc.'s launch of the new \$50 Million GSK Canada Life Sciences Innovation Fund will significantly help advance the commercialization of scientific innovation and identify strategic investment opportunities within Canada's life sciences industry, including academic and health institutions, translational research centres and start-up companies.	\$50,000,000.00	National
01-Dec-2011		In partnership with the Hamilton Health Sciences Foundation and the McMaster Children's Hospital, Bayer HealthCare funded a new research chair in Pediatric Thrombosis and Hemostasis. The new research chair will focus on bleeding and clotting disorders within children, including stroke.	\$1,000,000.00	ON
11-Dec-2011		Contribution of \$2.25 million dollars over 3 years to Partners for Mental Health Foundation (PMHF) to support research, education and advocacy for mental illness.	\$2,250,000.00	National
12-Dec-2011		Merck has signed a research evaluation agreement with EnWave, to determine the feasibility of ENWave's Radiant Energy Vacuum (Rev) Technology for the rapid, controlled dehydration of biological materials.	Amount Undisclosed	QC










20-Dec-2011	 MERCK <i>Bewell</i>	\$1.4 million donation to Simon Fraser University, including equipment, that will support research and teaching in a number of areas affecting human health.	\$1,400,000.00	BC
2011-2012	 AstraZeneca	AstraZeneca has created and funded a disease management program in mental health called Prends Soin de Toi. In 2011 and 2012, AZC has invested \$5.7 M in the program which is aimed at funding locally initiated projects with the goal to improve knowledge, health care delivery, disease prevention and patient treatment in mental health.	\$5,700,000.00	National
Jan-2012	 janssen	Janssen provided a research grant to the Vancouver Prostate Center and the British Columbia Cancer Agency (BCCA) to study Circulating Tumour Cells as biomarkers in the progress of prostate cancer. Funds provided will help establish the BCCA as a Canadian Centre of Excellence in prostate cancer research	1,200,000.00	BC
2012	 janssen	Janssen is supporting the British Columbia Cancer Agency to develop new knowledge in the areas of drug budget impact for the top five medications. Research includes the development of new pharmacoeconomic models for the next generation of therapies.	Undisclosed	BC
2012	 Bayer	Bayer Healthcare, the University of British Columbia Bleeding Disorders Collaborators and Vancouver General Hospital have established a partnership to improve the quality of care for patients who suffer from hemophilia and other bleeding disorders.	\$750,000.00	BC
17-Jan-2012	 Boehringer Ingelheim	Boehringer Ingelheim has commitment of \$450,000 to support the advancement of heart and stroke research in Calgary and Edmonton over the next three years. \$300,000 will support two professorships at the University of Calgary's Faculty of Medicine. Another \$150,000 will support innovative research in atrial fibrillation at the Mazankowski Alberta Heart Institute in Edmonton.	\$450,000.00	AB
20-Jan-2012	 Pfizer	A federal investment of \$500,000 through Western Economic Diversification Canada and an additional investment of \$500,000 by Pfizer Canada will enable the Alberta Pfizer Collaboration Fund, now a \$2.5 million initiative, to identify and support promising health care innovations with market potential.	\$500,000.00	AB









Feb-2012		Support of the Treat to Prevent initiative being spearheaded by Dr. Julio Montaner from the BC Centre for Excellence for HIV/AIDS. This initiative was recognized in the Globe and Mail as one of the top innovations in Canada in 2012 and is focused on an approach to HIV/AIDS treatment aimed at eradicating the illness.	\$1,000,000.00	BC
3-Feb-2012		Medicago Inc. plans to invest approximately \$4 million to enhance the capacity of the pilot production facility located in Quebec City. This new investment includes capital expenditures and labour costs, as well as preclinical studies for a rabies vaccine and other products.	\$4,000,000.00	QC
23-Feb-2012		GlaxoSmithKline invests \$12 Million in Canada for Influenza Research. Funding ensures key infrastructure will continue as surveillance research will be conducted in 40 hospitals across Canada	\$12,000,000.00	National
27-Feb-2012		Collaboration with AngioChem to discover, develop, and commercialize treatments for lysosomal storage diseases.	\$300,000,000.00	QC
28-Mar-2012		Merck contributes \$35 million to Merck Lumira Biosciences Fund in Quebec which will fuel future pharmaceutical innovation in Quebec. This new fund launched by Merck Canada, Lumira Capital, Teralys Capital and other partners will support early stage biotechnology companies and attract more life science investors to the province.	\$35,000,000.00	QC
1-Apr-2012		State-of-the-art, Leeds Gold certified administrative building in Laval - \$10,000,000 – building completed April 2012, official announcement to come Sept 2012	\$10,000,000.00	QC
16-Apr-2012		Montreal Heart Institute (MHI) receives designation as the hub for translational medicine studying cardiometabolic disease in the global network of the multinational pharmaceutical company Roche.	Amount Undisclosed	QC
23-Apr-2012		Sanofi Pasteur invested \$1.3 million in a “condensing economizer.” The cutting-edge equipment, which is the size of a small building, converts waste heat into energy. The investment was part of Sanofi Pasteur’s ongoing commitment to reducing its environmental impact, and promises to reduce the site’s carbon dioxide emissions by more than 2,300 tonnes per year. Enbridge Gas Distribution, Canada’s largest natural gas distribution utility, was proud to partner with Sanofi Pasteur on this initiative.	\$1,300,000.00	ON






23-Apr-2012		Janssen Inc., member of the Janssen Pharmaceutical Companies, inaugurated its new Montreal Immunology division office.	Amount Undisclosed	QC
2-May-2012		Sanofi Canada announced the relocation of its head office in Laval to a new LEED-certified building in Laval's Biotech City, where Sanofi will join more than 80 companies with nearly 5,000 professionals dedicated to the life sciences industry.	Amount Undisclosed	QC
28-May-2012		Teralys Capital and Eli Lilly and Company Contribute a New \$150 Million Fund to Life Sciences in Canada. This new fund launched by Lilly, Teralys Capital and other partners will enable the development of a new investment model in Quebec that will support early stage drug development and benefit researchers, entrepreneurs, business partners and service providers in the province.	\$150,000,000.00	QC
29-May-2013		The Centre for Drug Research and Development (CDRD), its commercial arm, CDRD Ventures Inc. (CVI), and GlaxoSmithKline (GSK) in Canada announced they entered into a strategic collaboration that will provide new financial resources as well as leading drug development expertise to be applied to the development and commercialization of health research conducted in Canadian research institutions.	Amount Undisclosed	National
11-Jul-2012		Collaboration between Eli Lilly Canada Inc. and Alberta Innovates - Health Solutions - the Alberta/Lilly Translational Research Collaboration Fund will provide 1.475 million to support health research at publicly funded Alberta post-secondary institutions.	\$1,475,000.00	AB
12-Jul-2012		Major investment in Pfizer Global Supply (PGS) Montreal manufacturing facility representing a financial commitment of 31,700,000.00 to upgrade technology and increase capacity to accommodate growth from new export mandates.	\$31,700,000.000	QC
28-Aug-2012		The newly-created grant program supports peer-reviewed research that promotes excellence in urological research, with the ultimate goal of improving patient care. Astellas Pharma Canada has pledged \$750,000 over a period of five years to support Canadian investigators in urology.	750,000.00	National



25-Oct-2012		Thrasos Therapeutics™ announced that it has completed a \$35 Million (U.S.) financing for the development of <u>THR-184</u> , its lead product candidate for the treatment of acute kidney injury (AKI). The round was led by new investor, SR One, with funds coming from the GSK Canada Life Sciences Innovation Fund, part of GlaxoSmithKline's commitment to advance the development and commercialization of scientific innovation in Canada.	\$35,000,000.00	National
14-Nov-2012	 Mr. and Mrs. Paul Lucas	The Paul Lucas Scholarship for the Faculty of Health Sciences has been created in honour of Mr. Paul Lucas, past Chair of the Board of Rx&D and retired CEO of GlaxoSmithKline Inc. Rx&D has contributed \$25,000 to the scholarship, and this commitment has been matched by Mr. Paul Lucas and his wife Mrs. Linda Lucas for a total of \$50,000. The scholarship will be awarded to a student of the Faculty of Health Sciences at Queen's University.	50,000.00	ON
14-Nov-2012	 	The Deborah M. Brown Scholarship in Biomedical Discovery and Commercialization will be created in honour of Mrs. Deborah M. Brown, Outgoing Chair of the Rx&D Board (2012), and President and Managing Director, EMD Serono. This scholarship will be awarded to a student in a new cross-disciplinary Bachelors/Master's program in biomedical discovery and commercialization at McMaster. Rx&D and EMD Serono have each contributed \$25,000, and McMaster has contributed an additional \$25,000 for a total amount of \$75,000 over 5 years.	50,000.00	ON
14-Nov-2012	 	The Ronnie Miller Scholarship in Personalized Medicine was created in honour of Mr. Ronnie Miller, past Chair of the Rx&D Board (2011) and President & CEO, Hoffmann-La Roche Limited. Awarded to a graduate student of the Department of Biochemistry and Molecular Biology at the University of British Columbia, whose work will provide a significant contribution to the British Columbia Personalized Medicine Initiative (BCPMI). Rx&D and Hoffmann-La Roche Limited have each contributed \$25,000, for a total of \$50,000 over 5 years.	50,000.00	BC



23-Nov-2012		<p>AstraZeneca Canada and Pfizer Canada, two leaders in the country's biopharmaceutical industry, are forming a partnership with the Québec government to create the NÉOMED Institute, a new kind of life sciences research centre. A total of \$100 million will be invested to establish and support the research centre over five years. AstraZeneca Canada is donating \$35 million to the NÉOMED Institute. This includes land, the neuroscience basic research facility, and leading-edge laboratory equipment. It also includes the donation of intellectual property to three AstraZeneca pain molecules and projects, as well as \$5 million to support the activities of the institute. Pfizer Canada is providing a financial contribution of approximately \$3.5 million, and the Québec government is contributing \$28 million toward the project.</p>	\$40,000,000.00	QC
23-Nov-2012		<p>AstraZeneca Canada and Pfizer Canada, two leaders in the country's biopharmaceutical industry, are forming a partnership with the Québec government to create the NÉOMED Institute, a new kind of life sciences research centre. A total of \$100 million will be invested to establish and support the research centre over five years. AstraZeneca Canada is donating \$35 million to the NÉOMED Institute. This includes land, the neuroscience basic research facility, and leading-edge laboratory equipment. It also includes the donation of intellectual property to three AstraZeneca pain molecules and projects, as well as \$5 million to support the activities of the institute. Pfizer Canada is providing a financial contribution of approximately \$3.5 million, and the Québec government is contributing \$28 million toward the project.</p>	\$3,500,000.00	QC
26-Nov-2012		<p>Merck Canada announced today that it is reinforcing its commitment to growing Montréal's life sciences basic and translational research sector, by investing \$12.5 million to fund research at three prominent university-affiliated and hospital-based research centres. This investment by Merck supports the Research Institute of the McGill University Health Centre (RI-MUHC), the CHUM Research Centre (CRCHUM) and the Montréal Heart Institute Research Centre (MHI), and their mission of promoting the development of scientific advancements that will improve healthcare.</p>	\$12,500,000.00	QC










4-Dec-2012	 NOVARTIS	Novartis Pharmaceuticals Canada Inc. has become the latest pharmaceutical company to partner in the innovative Explore program of the CQDM, with an investment of \$300,000 supporting highly innovative research on drug discovery.	\$300,000.00	QC
22-Apr-2013	 MERCK <i>Be well</i>	Merck will provide \$4 million in funding to the Institute for Research in Immunology and Cancer - Commercialization of Research (IRICoR) for future corridor projects developed in collaboration with two other Canadian Centres of Excellence for Commercialization and Research (CECRs) based in Ontario and in British Columbia.	\$4,000,000.00	ON, BC
June 2013	 Abbott 	Abbott Laboratories sponsors the AbbVie Professorship in Medication Adherence within the University of British Columbia's Faculty of Pharmaceutical Sciences	\$615,000.00	BC
3-Jul-2013	 astellas	Astellas Pharma Canada, Inc. announced a new partnership with the recently launched Canadian National Transplant Research Program (CNTRP), a novel research initiative that brings a collaborative and trans disciplinary approach to advancing research and patient care in the field of transplant. Astellas has pledged \$1 Million over a period of five years to support Canadian investigators in the transplant field as they work to address barriers to tissue and organ donation, with the ultimate goal of improving long-term outcomes and quality of life for transplant patients.	1,000,000.00	National
6- Sep-2013	 SERVIER	Servier Canada has just begun construction of a Centre of Excellence in Clinical Research at its Laval location. This new 30,000 square-foot complex represents a \$16.3 million investment and received the assistance of Investissement Québec and the strategic support of Montréal International. It will house activities for the Canadian International Centre for Therapeutic Research (ICTR) and the Servier Canada National Centre for Professional Training	\$16,300,000.00	QC
27-Sept-2013	 MERCK <i>Be well</i>	Merck Canada announced at the Sherbrooke International Life Sciences Summit that it is reinforcing its commitment to the Quebec life sciences research innovation sector by providing a \$4 million grant to the Fonds de recherche du Québec - Santé (FRQS) for academic research. The FRQS grant will go towards supporting patient-oriented research conducted by the Strategy for Patient-Oriented Research (SPOR) initiative.	\$4,000,000.00	QC





2-Oct-2013		<p>The Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) and its host institution, the Université de Montréal (UdM) today announced the licensing to Pfizer Inc. of a novel early-onset morbid obesity preclinical program developed at the Institute for Research in Immunology and Cancer (IRIC). Under the terms of the global license, Pfizer will fund pre-clinical research activities at IRIC and will be fully responsible for the clinical development and marketing of any resulting products. Pfizer will make an upfront payment to IRICoR, and IRICoR will be eligible to receive development and commercial milestone payments, as well as a tiered royalty on any product sales.</p>	Undisclosed	QC
3-Oct-2013		<p>Merck Canada confirmed its commitment to the Quebec life sciences research innovation sector by allocating a total of \$16 million in grants to four of Quebec's university hospital centres: Université de Montréal, Université de Sherbrooke, Université Laval and McGill University. The grant received by each institution will be used to support health research with a translational component conducted in areas of unmet medical need.</p>	\$16,000,000.00	QC
22-Oct-2013		<p>Biopharmaceutical company Gilead Alberta is spending \$47 million on a 45,000-sq.-ft. expansion of its research and manufacturing facility in Edmonton, and will create 80 new jobs once construction is complete. The Edmonton facility develops and manufactures Gilead's investigational medicines for clinical research programs in the areas of hepatitis C, HIV/AIDS and cancer treatments. It employs 250 people in research and development, drug manufacturing and quality assurance.</p>	47,000,000.00	AB
24-Oct-2013		<p>Janssen Pharmaceuticals NV has joined The Structural Genomics Consortium (SGC) to partner in the investigation of epigenetics-based drug research, a new and burgeoning field in the development of future medicines. Located at the Universities of Toronto and Oxford, the not-for-profit organization supports the discovery of new medicines by carrying out open-access research in structural and chemical biology. More than 200 researchers in academia and in six pharmaceutical companies collaborate within SGC to accomplish these goals.</p>	Undisclosed	National



8-Nov-2013		Pfizer renewed their partnership with the University of Sherbrooke for a further five years for the chair of technology analysis methods in pharmaceutical engineering. This partnership between Pfizer and Université de Sherbrooke provides an investment worth \$ 2.94 million in the field of innovative technologies. An amount of more than \$ 750,000 is expected in the context of funding agencies such as NSERC and FRQNT programs.	\$3,700,000.00	QC
		Donation of \$1 Million to the Ottawa Hospital Cancer Centre in support of hospital expansion to improve access, enhance cancer services and offer a more comfortable treatment environment for patients.	\$1,000,000.00	ON
		Donation of \$300,000 to the Jaravinski Cancer Center at Hamilton Health Sciences to provide essential funding for two key cancer care strategies: the creation of a nurse-led Transition Clinic and an Oncology Response Coordinator program.	\$300,000.00	ON
		Rotavirus surveillance investment in Quebec to enable implementation and sustainability of a "gold standard" in surveillance, demonstrated value of rotavirus vaccination, and apply learning's towards future disease targets.	\$1,800,000.00	QC
		Lundbeck Canada is investing over \$3 million dollars in a Canadian clinical trial with a novel drug treatment for some types of leukemia and lymphoma Starting mid 2011 and expect to end Dec 2012	\$3,000,000.00	National
21-Nov-2013	 	The Chris Halyk (Janssen Inc.) Health Innovation Scholarship at the Ivey Business School (Ivey) at Western University was created in honour of Mr. Chris Halyk past Chair of the Rx&D Board (2013) and President of Janssen Inc. The Chris Halyk (Janssen Inc.) Health Innovation Scholarship will be awarded to a full-time student entering Ivey's MBA program and will be based upon academic achievement and demonstrated community leadership. The recipient will have previous education and/or work experience in the health sector, an intention to complete the requirements of the Health Sector Certificate, and an interest in pursuing a career in health care. Rx&D and Janssen Inc. have each contributed \$25,000 , and Ivey has matched this contribution with an additional \$50,000 for a total of \$100,000 over 5 years.	\$50,000.00	ON



27-Nov-2013		Novartis Pharmaceuticals Canada Inc. (Novartis) announced an investment of \$1.2 million in Alberta to collaborate with the Alberta government to advance care and innovation in multiple sclerosis (MS). This investment by Novartis, for MS research, marks the first collaboration under a memorandum of understanding (MOU) between Novartis and the Alberta government intended to stimulate health research and innovation in the province of Alberta.	\$1,200,000.00	AB
13-Jan-2014		TVM Life Science Ventures VII today announced the fund's third investment – GLWL Research Inc., a company based in Montreal, Quebec. GLWL Research Inc. plans to develop, to proof-of-concept, GLWL-01, an investigational compound originally discovered by Eli Lilly and Company with the potential to treat Type-2 Diabetes.	Undisclosed	QC
14-Feb-2014		<p>Announcement of various projects that were funded under the first call for nominations Partnership Fund for an innovative Quebec and health (FPQIS).</p> <p>Assistance totaling \$ 62.5 million for investments of more than \$ 140 million, will be paid within seven research projects. These major projects are carried out in partnership between biopharmaceutical companies and medical equipment and public research organizations, including specialized academic centers and hospitals.</p> <p>The projects selected under the first call for nominations of FPQIS are:</p> <p>ARTERIA program for customizing diagnostics and cardiovascular therapies: a project of the Montreal Heart Institute 49.2 million assisted 18.2 million. This project is in partnership with Hoffmann-La Roche, Servier Canada, MedImmune, a subsidiary of AstraZeneca, Thrasos Therapeutics, Valeant Canada, Pharmascience, the Foundation of the Montreal Heart Institute, Spartan Bioscience and Pfizer Canada. 150 jobs will be created with this project.</p> <p>IRIC-industry: Multidisciplinary Partnerships in Drug Discovery for a lasting impact: a project of the Institute for Research in Immunology and Cancer, University of Montreal 29.5 million assisted 13, \$ 9 million . This project is in partnership with Bristol-Myers Squibb and Merck Canada pharmaceutical companies.</p> <p>Vaccine production in plants to protect against viral pneumonia elderly people: a project of the Research Institute of the McGill University Health Centre, in collaboration with the Centre for Infectious Disease</p>	\$140,000,000.00	QC



Research, University Laval , 12.9 million assisted 6 million. This project is in partnership with Medicago.






Fast for the control of hospital-acquired infections and multiresistant molecular diagnosis: a project of the Research Centre of the Centre hospitalier universitaire de Québec 7.4 million assisted 3.7 million. This project is in partnership with the Quebec firm GenePOC.

Network in personalized healthcare Q-CROC: a project of the Segal Cancer Centre at the Jewish General Hospital \$ 18.4 million assisted 9.2 million. This project is in partnership with Pfizer Canada, Merck Canada, Bayer Canada, Caprion Proteomics, Novartis Canada , Hoffmann-La Roche, Sanofi Canada and Seattle Genetics.





OPTI-THERA program to optimize therapeutic approaches care frontlines: a project of the Research Center Hospital of the University of Montreal 18.4 million assisted 9.2 million dollars. This project is in partnership with Servier Canada, Pfizer Canada, Laboratoires Servier (France), Valeant Canada, Telus Health Affymetrix, Ariana Pharma, Medpharmgene, Familiprix, echogenic-21 and InterMED-Rx.

Better diagnose and treat osteoarthritis of the knee: a clinical and economic imperative for the health care system: a project of the École de technologie supérieure 4.6 million assisted 2.3 million. This project is in partnership with the Quebec firm Emovi and Sanofi Canada.








18-Mar-2014		The Alberta Diabetes Institute at the University of Alberta announced a new collaboration with Janssen Inc. in Canada to advance early-stage technologies related to Type I and Type II diabetes. The Johnson & Johnson Diabetes Research Fund is a newly-created \$600,000 partnership, funded between Janssen, the Government of Alberta, and the Alberta Diabetes Foundation. The three year competitive fund, administered by U of A's Alberta Diabetes Institute, will support research in either Type I or Type II diabetes with a focus on novel, discovery research with a high potential for commercialization.	\$200,000.00	AB
3-April-2014		Merck Canada announced \$2-Million grant to support personalized treatment in Cancer. At the 6th Annual National Conference to Defeat Cancer, organized by Coalition Priorité Cancer, Merck Canada reinforced the company's continued commitment to the Quebec life sciences research innovation sector by announcing a \$2-million grant to the Quebec - Consortium de recherche en oncologie clinique (Q-CROC).	\$2,000,000.00	QC
8-April-2014		The Government of New Brunswick, Canada's Research-Based Pharmaceutical Companies (Rx&D), the Rx&D-Health Research Foundation (HRF), and the New Brunswick Health Research Foundation (NBHRF) have joined in partnership to study the effects of the New Brunswick drug plan on the overall health of the population as well as its impact on the health system. This research partnership represents a significant collaboration of industry, not-for-profit foundations and academia in evaluating public policy in New Brunswick. Funding for the project includes a \$180,000 grant from the Rx&D-HRF and \$90,000 from the NBHRF "Strategic Initiative" program.	\$180,000.00	NB
24-April-2014		The Government of Canada today announced the creation of the Canadian Clinical Trials Coordinating Centre (CCTCC) – a collaborative effort of the Canadian Institutes of Health Research (CIHR), Canada's Research-Based Pharmaceutical Companies (Rx&D), and the merged organizations of the Association of Canadian Academic Healthcare Organizations and the Canadian Healthcare Association (ACAHO/CHA). The CCTCC will be housed at the offices of the Health Charities Coalition of Canada, in Ottawa.	Amount Undisclosed	National
12-June-2014		CQDM and Sanofi Canada are pleased to announce their partnership to support highly innovative research in Quebec and Canada. Sanofi Canada will be contributing up to \$500,000 over a period of up to five years to research projects that will positively impact drug discovery and development as well as find concrete solutions to complex medical problems.	\$500,000.00	QC



16-June-2014		A new \$225,000 investment in health research in New Brunswick will examine the use of mobile technology to manage chronic disease and promote smoking cessation. Connected Choices is supported through \$150,000 in funding provided by Pfizer Canada Inc. and funding made available through the New Brunswick Health Research Foundation's (NBHRF) Strategic initiative Program.	\$225,000.00	NB
21-July-2014		The National Research Council of Canada (NRC) and KalGene Pharmaceuticals are proud to announce an agreement to co-develop a new treatment against aggressive brain cancers. By combining their research, NRC and KalGene are targeting glioblastomas, which are severe brain tumours associated with a median patient survival of about 15 months.	Amount Undisclosed	National
30-July-2014		Health Science North and its affiliate, the Advanced Medical Research Institute of Canada, have received a \$100,000 grant to conduct research into personalized medicine, which uses a patient's individual DNA to diagnose and treat their illnesses. Roche Canada is supporting the work of the hospital and the Advanced Medical Research Institute of Canada, in what is being called the new frontier of medicine, where drugs and treatments are targeted at individuals rather at illnesses or diseases as a whole.	\$100,000.00	ON
8-Sept-2014		Janssen Inc. announced it has signed an agreement, facilitated by the Johnson & Johnson Innovation center in California, with the University of Toronto's Centre for Collaborative Drug Research (CCDR) to form an open-source collaboration focused on novel therapeutic approaches to the treatment and management of mood disorders and Alzheimer's disease. The research project, called Neuroscience Catalyst, represents an innovative collaboration between industry, academia and the research community. Neuroscience Catalyst will help identify medical and scientific opportunities in early-stage development, which can progress to clinical treatment for brain disorders.	Amount Undisclosed	ON
9-Sept-2014		Genentech-Xenon research partnership investing into new pain medicines - a collaborative agreements with California-based Genentech, a subsidiary of Roche	Amount Undisclosed	BC



16-Sept-2014		Announcement of agreement between MedGenesis and Pfizer Inc., granting Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in research for potential treatments for Parkinson's disease.	Amount Undisclosed	National
2 Oct 2014	 Boehringer Ingelheim	McGill University announced the creation of the Albert Boehringer (1st) Chair in pharmacoepidemiology, made possible through a \$3 million gift from Boehringer Ingelheim (Canada) Ltd.	\$3,000,000.00	QC
10-Oct-2014		Creation of the 'Dr Madeleine Tremblay Servier and Groupe Servier fund for the development of medicinal products' (\$750,000) at the Faculty of Pharmacy of the Université de Montréal.	\$750,000.00	QC
19-Nov-2014	 	The J. Mark Lievonon Scholarship will provide a second-year Master of Business Administration or International Master of Business Administration student in the Schulich Health Industry Management Program with a scholarship of approximately \$7,000 to further their studies in the program. Rx&D and Sanofi Pasteur Limited have each contributed \$25,000, and Mark Lievonon has contributed an additional \$25,000. Schulich will match the annual income generated by their contributions, effectively creating an endowment valued at \$150,000.	\$150,000	ON
Total			\$1,753,460,000.00	

From: [Cagic, Nina MIT:EX](#)
To: [Morrison, Avril MIT:EX](#)
Cc: [Jethani, Salima MIT:EX](#)
Subject: Response letter re: CLIFF Log ID 14355
Date: Wednesday, May 6, 2015 8:26:50 AM
Attachments: [817475.pdf](#)

Hi Avril,

Here is the suggested response.[s.13](#)

attach the original letter for your convenience. Please format accordingly and send up the line accordingly.

Thanks.

[s.13](#)

Ref: 14355

Mr. Russell Williams
President
Canada's Research-Based Pharmaceutical Companies (Rx&D)
1220 55 Metcalfe Street
Ottawa, ON K1P 6L5

Dear Mr. Williams:

Thank you for your letter and update on Canada's Research-Based Pharmaceutical Companies' (Rx&D) involvement and commitment to the Asia-Pacific Economic Cooperation Forum. As you know, the Asia-Pacific region is an important region for the province of British Columbia and the Ministry of International Trade and, as such, we appreciate being kept informed of developments in the industry for this region.

My government colleagues and I value the important role Canada's research-based pharmaceutical companies play in advancing health-related innovation and the work your organization does to develop opportunities in this regard.

Once again, thank you for writing.

Sincerely,

Teresa Wat
Minister

**Ministry of International Trade and
Minister Responsible for
Asia Pacific Strategy and
Multiculturalism** Office of the Minister

Mailing Address:
PO Box 9063 Stn Prov Govt
Victoria BC V8W 9E2
Phone: 250 953-0910
Fax: 250 953-0928

Location:
Room 342
Parliament Buildings
Victoria BC

www.gov.bc.ca/mit

Jones, Angela MIT:EX

From: Doerksen, Heather MIT:EX
Sent: Tuesday, July 14, 2015 10:30 AM
To: Bains, Jasmine MIT:EX
Cc: Jones, Angela MIT:EX
Subject: 14355 ** Approved **

Hi Jasmine,

The below letter has been approved for E-Sig. Still working on the others !

14355 – Williams, Russell – Update on Rx&D's involvement and commitment to the Asia-Pacific Economic Cooperation (APEC) forum



14355 -
Incoming.pdf



14355 - Williams
- Outgoing.do...

Hope this helps,

Heather Doerksen

Administrative Assistant to the
Honourable Teresa Wat,
Minister of International Trade &
Minister Responsible for Asia Pacific Strategy and Multiculturalism
Ph . 250.953.0910
Fax. 250.953.0928

From: Bains, Jasmine MIT:EX
Sent: Thursday, July 2, 2015 4:47 PM
To: Doerksen, Heather MIT:EX
Cc: Jones, Angela MIT:EX
Subject: Correspondence: For MTW's approval for esig

Hi Heather,

I know you are not returning to the office until Monday, July 6, but I wanted to get the following approvals to you for your action.

The following logs are all now referred over to the MO in cliff. Over to you to coordinate approval for Minister's esig. Incomings and Outgoings below.

Please note, you do not have to insert esig yourself, CSB will do that. Once MTW has approved, you can cliff back to CSB for mail out, with a cc to me.

Thanks,

Jasmine

14165 – Han Bridge, Jackie – Meeting Request from Dehua

<< Message: Meeting Request >> << File: 14165, Han Bridge - Outgoing.docx >>

14355 – Williams, Russell – Update on Rx&D's involvement and commitment to the Asia-Pacific Economic Cooperation (APEC) forum

<< File: 14355 - Incoming.pdf >> << File: 14355 - Williams - Outgoing.docx >>

14435 – s.22

<< File: 14435 - Incoming.pdf >> << File: 14435 - s.22 Outgoing.docx >>

14515 – Ralston, Bruce MLA – Estimates Response, Chandigarh

<< File: Ralston Incoming.pdf >> << File: 14515 - Ralston Outgoing.docx >>



Ref: 14355

JUL 14 2015

Mr. Russell Williams
President
Canada's Research-Based Pharmaceutical Companies (Rx&D)
1220 55 Metcalfe Street
Ottawa, ON K1P 6L5

Dear Mr. Williams:

Thank you for your letter and update on Canada's Research-Based Pharmaceutical Companies' (Rx&D) involvement and commitment to the Asia-Pacific Economic Cooperation Forum. As you know, the Asia-Pacific region is an important region for the province of British Columbia and the Ministry of International Trade and, as such, we appreciate being kept informed of developments in the industry for this region.

My government colleagues and I value the important role Canada's research-based pharmaceutical companies play in advancing health-related innovation and the work your organization does to develop opportunities in this regard.

Once again, thank you for writing.

Sincerely,

Teresa Wat
Minister